_evaluation-of-a-comprehensive-genomic-profiling-assay-for-characterization-of-biomarkers-in-ffpe-tissue-tso500.jpg "Evaluation of a comprehensive genomic profiling assay for characterization of biomarkers in FFPE tissue (TSO500) from ngs terms Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 4 min 30 sec
✓ Published: 27-Jun-2023
✓ Published: 27-Jun-2023
Description:
Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. Illumina's TruSight Oncology 500 (TSO500) Comprehensive Assay employs a hybrid-capture approach for target enrichment of 523 clinically relevant cancer genes to enable detection of small variants (SNVs, insertions, and deletions), CNV (copy number variations), TMB (tumor mutational burden), and MSI (microsatellite instability) in DNA and detectio
Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. Illumina's TruSight Oncology 500 (TSO500) Comprehensive Assay employs a hybrid-capture approach for target enrichment of 523 clinically relevant cancer genes to enable detection of small variants (SNVs, insertions, and deletions), CNV (copy number variations), TMB (tumor mutational burden), and MSI (microsatellite instability) in DNA and detectio
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_ngs-crypto-blockchain-mining-explained-short.webp "Learn More About NGS Crypto's Blockchain Mining Packages Offering 6-16% Per Annum. Packages Available Over 2, 3 or 5 years, No Management Fees, Returning 100% Of Your Initial Investment Upon Completion. Minimum investment amounts apply – to find full terms & conditions please visit https://ngscrypto.com/terms-conditions.nnDisclaimer:nnThe information in this video is for educational purposes and is general information only. It should not be taken as constituting financial advice from the v")
_weapons-of-mass-migration-live-panel-qampa.webp "Crossroads with JOSHUA PHILIPP")
_next-generation-sequencing-acronyms-and-terms-seq-it-out-15.webp "Thermo Fisher Scientific")
_next-generation-sequencing-a-step-by-step-guide-to-dna-sequencing.webp "ClevaLab")
_sequencing-coverage-124-gene-coverage-amp-read-depth-124-sequencing-coverage-for-ngs-experiment-124.webp "BMH learning")
⏲ 2 minutes 14 seconds 👁 936
_19-sean-scott-vp-amp-gm-clinical-genomics-qiagen-bioinformatics-session-cancer-dx.webp "Scaling NGS Test Interpretation and Reporting In OncologynnThe interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limiting factor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefl")
⏲ 9 min 17 sec ✓ 16-Feb-2016
_ngs-report-in-cancer-what-to-know-in-layman39s-terms.webp "Dr Sudha S Murthy")
_ngs-crypto-blockchain-mining-explained-short.jpg)
_weapons-of-mass-migration-live-panel-qampa.jpg)
_next-generation-sequencing-acronyms-and-terms-seq-it-out-15.jpg)
_next-generation-sequencing-a-step-by-step-guide-to-dna-sequencing.jpg)
_sequencing-coverage-124-gene-coverage-amp-read-depth-124-sequencing-coverage-for-ngs-experiment-124.jpg)
_19-sean-scott-vp-amp-gm-clinical-genomics-qiagen-bioinformatics-session-cancer-dx.jpg)
_ngs-report-in-cancer-what-to-know-in-layman39s-terms.jpg)
![[+]](/images/menu.gif){kind=small}